Sheraton Indianapolis City Centre
May 15-16, 2014
Thursday, May 15, 2014
Registration, Continental Breakfast, Poster Setup, and Sponsor Booth Setup, 10:00 AM
Welcome, 11:00 AM
Drug transporters at the blood-arachnoid-CSF barrier., 11:10 AM
Erin Schuetz, PhD, Pharmaceutical Sciences Dept., St Jude Children's Research Hospital.
Drug Transporters, Drug Interactions and Agency Review Experiences., 11:50 AM
Joe Polli, PhD, Mechanism and Extrapolations Technology Section, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Inc.
Lunch, Students and Postdocs Network with Industry Scientists (AbbVie, Eli Lilly, Genentech, GSK, Pfizer), View Posters, and Visit Sponsor Booths, 12:30 PM
Understanding the contribution of transporters to drug disposition., 2:00 PM
Wenqing Gao, PhD, Translational PKPD, AbbVie.
Advances in human in vitro-in vivo extrapolation (IVIVE) of CYP and non-CYP elimination pathways to predict pharmacokinetics., 2:40 PM
Theunis Goosen, PhD, Dept. of Pharmacokinetics, Dynamics and Metabolism, Pfizer.
Break, 3:20 PM
Activation of JNK-BimEL signaling by anti-HIV drug metabolites., 3:40 PM
Namandje N. Bumpus, PhD: Dept. of Pharmacology and Molecular Sciences, School of Medicine, Johns Hopkins University.
Drug disposition development strategies for antibody-drug conjugates., 4:20 PM
Sandhya Girish, PhD, Genentech.
Poster Session (Author Available), Sponsor Booths, and Mixer, 5:00 PM
Dinner, 7:00 PM
Friday, May 16, 2014
GLDMDG Business Meeting and Sponsor Booth Setup, 7:30 AM
Continental Breakfast and Poster Viewing, 7:30 AM
The added value of metabolic phenotype in combination with genotype to individualize drug treatment., 8:30 AM
Richard Kim, MD, Professor of Medicine, Physiology & Pharmacology, and Oncology Wolfe Medical Research Chair in Pharmacogenomics Dept. of Medicine Schulich School of Medicine & Dentistry Western Ontario University.
Endogenous biomarkers for the assessment of CYP3A activity., 9:10 AM
Yvonne Lin, PhD, Dept. of Pharmaceutics, School of Pharmacy, University of Washington.
Break, 9:50 AM
Development of BACE inhibitors for Alzheimer’s disease: Evaluation of central and peripheral PK/PD relationships., 10:00 AM
Scott Monk, PhD, Eli Lilly and Co.
Loss of MRP1 in transgenic mice potentiates doxorubicin-induced cardiotoxicity.,10:40 AM
Wei Zhang, Graduate Student, University of Kentucky.
Novel product identification with human cytochrome P450 19A1 aromatase., 10:55 AM
Francis Yoshimoto, Ph.D., Postdoctoral Fellow, Vanderbilt University
How do we improve the prediction of clearance for drugs that undergo transport and /or non-CYP metabolism., 11:10 AM
Round table with relevant speakers.
Closing Remarks, 11:50 AM